Enfusion Results Presentation Deck
Reconciliations of Non-GAAP Financial Measures
The following table reconciles operating cash flow to unlevered free cash flow and adjusted free
cash flow:
($ in thousands)
Net Cash provided by (used in) operating activities
Purchase of property and equipment
Unlevered Free Cashflow
Adjustments
Less bonus timing and non-recurring expenses
Adjusted Free Cash Flow
($ in thousands)
Cost of revenues
General and administrative
Sales and marketing
Technology and development
Total stock compensation expense
*:enfusion
S
$
December 31, 2021
(5,812)
(1,641)
(7,453)
4,389
(3,064)
Three Months Ended
December 31, 2022
321
2,096
936
852
4,205
S
March 31, 2022
(4,097)
(3,171)
$
(7,268)
The Company's stock compensation expense was recognized in the following captions within the consolidated
statements of operations:
(2,160)
2022
(9,428)
Year Ended December 31,
1,421
14,130
Three Months Ended
5,875
3,567
24,993
June 30, 2022
2,890
(2,092)
798
(2,160)
(1,362)
September 30, 2022
7,842
(922)
6,920
(2,160)
4,760
December 31, 2022
7,521
(1,746)
5,775
(2,160)
3,615
PROPRIETARY AND CONFIDENTIAL Ⓒ2023 ENFUSION. ALL RIGHTS RESERVED.
19View entire presentation